142 related articles for article (PubMed ID: 2684694)
1. [A multicenter clinical trial of SMS 201-995 (octreotide acetate) in acromegaly and gigantism].
Shimatsu A; Imura H; Irie M; Nakagawa S; Goto Y; Shimizu N; Takeda R; Kato Y; Saito S; Ibayashi H
Nihon Naibunpi Gakkai Zasshi; 1989 Jul; 65(7):640-52. PubMed ID: 2684694
[TBL] [Abstract][Full Text] [Related]
2. [Long-term treatment of acromegaly and gigantism with octreotide (SMS 201-995)].
Shimatsu A; Imura H; Irie M; Nakagawa S; Goto Y; Shimizu N; Takeda R; Kato Y; Saito S; Ibayashi H
Nihon Naibunpi Gakkai Zasshi; 1992 Feb; 68(2):89-99. PubMed ID: 1592144
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic efficacy of the somatostatin analog SMS 201-995 (octreotide) in acromegaly. Effects of dose and frequency and long-term safety.
Ho KY; Weissberger AJ; Marbach P; Lazarus L
Ann Intern Med; 1990 Feb; 112(3):173-81. PubMed ID: 2404445
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the effectiveness of 2-hourly versus 8-hourly subcutaneous injections of a somatostatin analog (SMS 201-995) in the treatment of acromegaly.
Wang C; Lam KS; Arceo E; Chan FL
J Clin Endocrinol Metab; 1989 Sep; 69(3):670-7. PubMed ID: 2668325
[TBL] [Abstract][Full Text] [Related]
5. Treatment of acromegaly with the long-acting somatostatin analog SMS 201-995.
Barkan AL; Kelch RP; Hopwood NJ; Beitins IZ
J Clin Endocrinol Metab; 1988 Jan; 66(1):16-23. PubMed ID: 2891720
[TBL] [Abstract][Full Text] [Related]
6. SMS 201-995 induces a continuous decline in circulating growth hormone and somatomedin-C levels during therapy of acromegalic patients for over two years.
Lamberts SW; Uitterlinden P; del Pozo E
J Clin Endocrinol Metab; 1987 Oct; 65(4):703-10. PubMed ID: 2888785
[TBL] [Abstract][Full Text] [Related]
7. Clinical and biochemical effects of incremental doses of the long-acting somatostatin analogue SMS 201-995 in ten acromegalic patients.
Shi YF; Harris AG; Zhu XF; Deng JY
Clin Endocrinol (Oxf); 1990 Jun; 32(6):695-705. PubMed ID: 2200620
[TBL] [Abstract][Full Text] [Related]
8. Octreotide as primary therapy for acromegaly.
Newman CB; Melmed S; George A; Torigian D; Duhaney M; Snyder P; Young W; Klibanski A; Molitch ME; Gagel R; Sheeler L; Cook D; Malarkey W; Jackson I; Vance ML; Barkan A; Frohman L; Kleinberg DL
J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397
[TBL] [Abstract][Full Text] [Related]
9. Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide.
Morange I; De Boisvilliers F; Chanson P; Lucas B; DeWailly D; Catus F; Thomas F; Jaquet P
J Clin Endocrinol Metab; 1994 Jul; 79(1):145-51. PubMed ID: 8027218
[TBL] [Abstract][Full Text] [Related]
10. Medical treatment of acromegaly with SMS 201-995, a somatostatin analog: a comparison with bromocriptine.
Chiodini PG; Cozzi R; Dallabonzana D; Oppizzi G; Verde G; Petroncini M; Liuzzi A; del Pozo E
J Clin Endocrinol Metab; 1987 Mar; 64(3):447-53. PubMed ID: 2880861
[TBL] [Abstract][Full Text] [Related]
11. [Long-term treatment of acromegaly with the somatostatin analog octreotide (Sandostatin). On the predictive significance of acute tests].
Schmidt K; Althoff PH; Harris A; Hofmeister-Wagner W; Schifferdecker E; Schöffling K
Med Klin (Munich); 1990 Dec; 85(12):700-6. PubMed ID: 2128367
[TBL] [Abstract][Full Text] [Related]
12. Depot long-acting somatostatin analog (Sandostatin-LAR) is an effective treatment for acromegaly.
Stewart PM; Kane KF; Stewart SE; Lancranjan I; Sheppard MC
J Clin Endocrinol Metab; 1995 Nov; 80(11):3267-72. PubMed ID: 7593436
[TBL] [Abstract][Full Text] [Related]
13. A prospective multicenter octreotide dose response study in the treatment of acromegaly.
Ezzat S; Redelmeier DA; Gnehm M; Harris AG
J Endocrinol Invest; 1995 May; 18(5):364-9. PubMed ID: 7594225
[TBL] [Abstract][Full Text] [Related]
14. Long-term treatment of acromegaly with Sandostatin (SMS 201-995). Normalization of most anomalous growth hormone responses.
Pieters GF; van Liessum PA; Smals AG; van Gennep JA; Benraad TJ; Kloppenborg PW
Acta Endocrinol Suppl (Copenh); 1987; 286():9-18. PubMed ID: 2892339
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients--a clinical research center study.
Newman CB; Melmed S; Snyder PJ; Young WF; Boyajy LD; Levy R; Stewart WN; Klibanski A; Molitch ME; Gagel RF
J Clin Endocrinol Metab; 1995 Sep; 80(9):2768-75. PubMed ID: 7673422
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of long-acting pasireotide in Japanese patients with acromegaly or pituitary gigantism: results from a multicenter, open-label, randomized, phase 2 study.
Tahara S; Murakami M; Kaneko T; Shimatsu A
Endocr J; 2017 Jul; 64(7):735-747. PubMed ID: 28592706
[TBL] [Abstract][Full Text] [Related]
17. The pulsatile GH secretion in acromegaly: hypothalamic or pituitary origin?
Riedel M; Günther T; von zur Mühlen A; Brabant G
Clin Endocrinol (Oxf); 1992 Sep; 37(3):233-9. PubMed ID: 1358484
[TBL] [Abstract][Full Text] [Related]
18. Treatment of resistant acromegaly with a long-acting somatostatin analogue (SMS 201-995).
Barnard LB; Grantham WG; Lamberton P; O'Dorisio TM; Jackson IM
Ann Intern Med; 1986 Dec; 105(6):856-61. PubMed ID: 2877605
[TBL] [Abstract][Full Text] [Related]
19. Dose-response study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly.
Quabbe HJ; Plöckinger U
J Clin Endocrinol Metab; 1989 May; 68(5):873-81. PubMed ID: 2565912
[TBL] [Abstract][Full Text] [Related]
20. Acute and long-term effects of SMS 201-995 in acromegaly.
Lamberts SW; del Pozo E
Scand J Gastroenterol Suppl; 1986; 119():141-8. PubMed ID: 2876498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
